Clinical trial

A Phase 1, Two-part, Open-label, Drug-drug Interaction Study in Healthy Male Adult Participants to Evaluate the Effects of BMS-986371 on the Pharmacokinetics of Methotrexate in the Presence and Absence of Sulfasalazine

Name
IM046-003
Description
The purpose of this study is to evaluate the effects of BMS-986371 on the drug levels of methotrexate, sulfasalazine and their main metabolites in healthy male adult participants.
Trial arms
Trial start
2022-09-06
Estimated PCD
2022-11-17
Trial end
2022-11-23
Status
Completed
Phase
Early phase I
Treatment
Methotrexate
Specified dose on specified days
Arms:
Part 1, Part 2
Leucovorin
Specified dose on specified days
Arms:
Part 1, Part 2
BMS-986371
Specified dose on specified days
Arms:
Part 1, Part 2
Other names:
CC-99677
Sulfasalazine
Specified dose on specified days
Arms:
Part 2
Size
30
Primary endpoint
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])
Up to 22 days
Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])
Up to 22 days
Maximum observed plasma concentration (Cmax)
Up to 22 days
Eligibility criteria
Inclusion Criteria: * Participant has physical exam, vital signs, clinical laboratory safety and other medical test results that are within normal limits, considered not clinically significant by the Investigator, or within other parameters specified in the protocol * Body mass index of 18 to 32 kg/m\^2, inclusive Exclusion Criteria: * Any significant acute or chronic medical illness * Current or recent (within 3 months of study intervention administration) gastrointestinal disease that could possibly affect the absorption, distribution, metabolism and excretion of study drug * Any other medical, psychiatric and/or social reason as determined by the Investigator Other protocol-defined inclusion/exclusion criteria apply
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SEQUENTIAL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 30, 'type': 'ACTUAL'}}
Updated at
2023-02-08

1 organization

4 products

1 indication

Product
BMS-986371
Product
Leucovorin